Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
Checked against the public recordLast updated May 28, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Interventions being studied
- Drug: Tocilizumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patient or designated proxy willing and able to provide informed consent prior to enrollment in the study. * COVID-19 PCR positive on nasopharyngeal swab * Aged \>/= 18 years old * Patient hospitalized with newly diagnosed documented severe COVID-19 infection: with respiratory rate \>/= 30 breaths/min OR peripheral capillary oxygen saturation (SpO2) \< 93% on room air for nonintubated pts. * Fever of 38.5 C or suspected respiratory infection * IL-6 level \>/= 80 pcg/ml * Cohort #1 - non intubated Cohort #2 - intubated * Women of childbearing potential must have a negative serum or urine pregnancy test * Patients receiving ongoing steroid therapy are eligible * Patients will be allowed to receive concurrent or sequential treatment with remdesivir Exclusion Criteria: * Patients with uncontrolled systemic fungal and bacterial infections * Patients with latent tuberculosis * Patients with known hypersensitivity to tocilizumab or any component of the formulation * Concurrent initiation of steroid therapy is not allowed * Patients with uncrontroled malignant disease, with a life expectancy of 3 months or less
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Memorial Sloan Kettering Cancer CenterNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 28, 2025. Always confirm current availability with the study team.